Introduction
Vitamin D is a steroid hormone that is present in some foods, but is synthesized mainly in response to ultraviolet light exposure. After ingestion or endogenous synthesis, vitamin D is hydroxylated by the liver to form 25- Epidemiologic studies suggest an inverse association between circulating levels of 25(OH)D and cardiovascular risk biomarkers, including an atherogenic lipid profile. 2, 3 Vitamin D deficiency is highly prevalent and can be effectively treated through oral repletion. However, a role for supplementation in modifying cardiovascular risk has not been well defined, and, it is unclear whether vitamin D status is causally related to disease or merely a marker of health. 4 This is relevant for practitioners as well as the general population, because of the increasing consumption of pharmacologic doses of vitamin D sold over-the-counter.
Cross-sectional studies are unable to assess the longitudinal effects of changes in 25(OH)D levels on standard cardiovascular risk biomarkers. Although, randomized clinical trials of vitamin D supplementation would provide a higher level of evidence, studies to date have shown conflicting results. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] These studies were limited by relatively small sample sizes, confounding effects of vitamin D with additional calcium supplementation, and study designs that did not specifically target vitamin D deficiency, or did not use a sufficient dose of vitamin D to achieve a consensus "optimal" level of >30 ng/ml.
In the absence of definitive evidence from randomized, controlled trials (RCT), data 25(OH)D and cardiovascular risk biomarkers, including an atherogenic lipid pro of fi file le e. Th Th his is is i i is s s re rele le eva va vant nt f f for r r p pr ra act ct tit itio i n ne ners rs s a a as s s w we wel ll a a as s s t th the e e ge ge gene ne nera r l l l po po opu pu pula a ati ti tion on n, be be beca ca au us se e of of o t t the he i i in nc ncre re eas s sin ing g g consumption n of of of p p pha ha harm rm rmac ac a ol l log og ogic i mining is becoming an increasingly valuable tool for rapidly and cost-effectively generating and testing hypotheses. Quest Diagnostics has the largest private database of patient laboratory test data. We analyzed de-identified results from this database to compare cross-sectional and longitudinal approaches to studying the relationship between 25(OH)D levels and blood lipids.
In the cross-sectional approach, we studied the association between 25(OH)D levels and the lipid panel in a large population derived from medical practices broadly across the United States. For the longitudinal approach, we identified a cohort from the same population to determine how changes in 25(OH)D levels are related to changes in lipid levels.
Given the absence of clear evidence from RCT, we believe our longitudinal cohort analysis introduces a novel approach to exploring these important biomarker relationships. We studied a very large national sample relatively quickly and inexpensively, whereas an analogous prospective, randomized, controlled trial would take years to complete and possibly be prohibitively expensive. Because vitamin D deficiency and dyslipidemia are so prevalent, it is important for clinicians to have better evidence on which to base treatment decisions in a timely manner. We believe that our longitudinal analysis fills this gap between cross-sectional reports and a resource-intensive clinical trial, the results of which would not be available for many years.
Methods
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Downloaded from
Cross-Sectional Study Population
Of these patients, 107,811 records met the following inclusion criteria: ages 40 to 80 years; had two or more simultaneous 25(OH)D, lipid panels, and glucose tests within 4 and 26 weeks apart, inclusive; triglycerides <400 mg/dl and glucose <200 mg/dl for both tests; and the absolute difference between the first and second glucose values <30 mg/dl (Figure 1) . The glucose restrictions were intended to exclude patients who fasted inconsistently, or may not have fasted, or who had poorly-controlled diabetes. We stratified 25(OH)D results into consensus clinical strata: deficient <20 ng/ml, n = 25,235), insufficient (20 -29 ng/ml, n = 40,406), and optimal ( 30 ng/ml, n = 42,170) 25(OH)D.
Longitudinal Study Population
From these 107,811 patients, we determined the distribution of LDL cholesterol level change between the initial and final visits (Figure 2) . To exclude patients who may have had changes in lipid-lowering therapy, the analysis was limited to patients in the second and third quartile of the LDL cholesterol change distribution. This excluded patients whose change in LDL cholesterol measurements were 15 or >10 mg/dl. 54,794 patients met this criterion, and from these, two sub-groups were selected: Group I (the "repletion" group) included 6,260 patients whose initial 25(OH)D concentration was <20 ng/ml and whose immediate subsequent 25(OH)D concentration was >30 and <100 ng/ml. Group II (the "control" group) included 2,332 patients whose initial and immediate subsequent 25(OH)D concentrations were both <20 ng/ml. 
Laboratory Methods
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Longitudinal Study Population
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For additional analysis assessing the impacts of seasonality and the interval between testing on the longitudinal study, see Supplemental Material.
Human Subject Protection
This study was reviewed by The Rockefeller University Institutional Review Board and Western
Institutional Review Board and considered "an exempt activity requiring no further IRB review." From the remaining patients (n = 54,794), we used changes in 25(OH)D levels to identify repletion and control groups, Group I (n = 6,260) and Group II (n = 2,332), respectively.
Results
To
The average age of patients in Group I was 60.6 (±10.6) years, compared to 58.9 (±10.9)
years for patients in Group II ( Table 2 ). Both groups had a similar proportion of women (approximately two-thirds). Baseline 25(OH)D levels for Group I were 14.3 ±3.8 ng/ml, compared to 13.2 ±3.9 ng/ml for Group II. Baseline lipid, glucose, and calcium levels were clinically similar between groups, though the control group had statistically higher LDL cholesterol, lower triglycerides, and lower calcium levels. Table 3 shows the frequency of the most common ICD-9 codes listed on the initial laboratory requisitions. Patients in Group I were more likely to receive ICD-9 codes indicative of dyslipidemia and hypertension compared to controls. However, there was no statistical difference between groups in the designation of vitamin D deficiency or the common comorbidities of diabetes and hypothyroidism.
For Group I, the repletion group, 25(OH)D levels increased an average of 27.3 ng/ml, from a mean value of 14.3 ±3.8 ng/ml to 41.6 ±10.9 ng/ml ( Figure 3 ). In contrast, initial and final mean 25(OH)D levels remained deficient for Group II, the control group, (13.2 ±3.9 vs.
14.1 ±3.7 ng/ml), an increase of only 0.9 ng/ml. Since vitamin D 2 is not endogenously produced, we analyzed 25-hydroxyvitamin D 2 and D 3 levels at initial and final visits for both Groups I and II to provide evidence that the increase in Group I was due to supplementation. In the repletion group, 25-hydroxyvitamin D 2 levels were detectable (>4 ng/ml) in only 4.6% of patients at clinically similar between groups, though the control group had statistically highe he er LD LD LDL L L cholesterol, lower triglycerides, and lower calcium levels.
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Discussion
We analyzed a large national clinical laboratory database to determine relationships between 25(OH)D levels and components of the lipid panel. In the cross-sectional analysis, the "optimal" group relative to the "deficient" 25(OH)D group displayed lower total cholesterol (-1.9 mg/dl), lower LDL cholesterol (-5.2 mg/dl), higher HDL cholesterol (4.8 mg/dl), and lower triglycerides (-7.5 mg/dl). The statistically significant cross-sectional association between 25(OH)D levels and components of the lipid panel is consistent with other cross-sectional studies and suggests a possible causal relationship. However, association studies cannot be used to infer causality.
Indeed, in contrast to cross-sectional data, the longitudinal analysis showed that increasing o a 2.81 mg/dl decrease in the control group, for a relative increase of 0.77 mg/ /d d dl l (p (p p = = = .01 01 01) ) ) in in in the epletion group (Table 4 ). An increase in 25(OH)D levels was also associated with an increase in HD HD DL L L ch ch chol ol oles es este te tero ol l l 0 0. 0.42 4 mg/dl (p = .02). No statisti ti tica ca c l lly significant t in i i te er-r--gr gr group differences were ob bse e serv r ed for c cha ha hang ng ges es i i n n LD LD LDL L L c c cho hole le l s st ste er ro ol or tr rigly y yce e erid de des s s.
25(OH)D levels from the deficient to optimal range ("repletion" group), compared to remaining in the deficient range ("control" group), was associated with small and clinically minimal effects on total cholesterol 0.8 mg/dl increase) and HDL cholesterol (0.4 mg/dl increase), and no significant changes in LDL cholesterol or triglycerides levels. These longitudinal data contrast with the purported benefits of vitamin D repletion on the lipid profile inferred from crosssectional studies. [17] [18] [19] [20] These novel findings and approach provide a different type of evidence for clinical practice guidelines than existing association studies. Clinicians are still awaiting the results of large, randomized, placebo-controlled outcome trials of vitamin D supplementation. 21 In the absence of clinical trials, this novel, inexpensive approach fills a gap for quickly examining the effect of vitamin D repletion on the lipid panel, a major predictive biomarker of cardiovascular risk. Moreover, and particularly important for patient-oriented research, the data were obtained from patient encounters, in a settings reflective of true clinical practice across the United States.
Our cross-sectional analysis is concordant with other vitamin D/lipid association studies showing that higher 25(OH)D levels are associated with a healthier lipid profile. [17] [18] [19] [20] This validates the use of the Quest Diagnostics database because it replicated the known associations between 25(OH)D and the lipid profile found in other cross-sectional studies. For example, the largest published association study (n = 15,088), based on NHANES III, found that mean 25(OH)D levels were lower in subjects with hypertriglyceridemia and hypercholesterolemia. 17 The same study also compared the age-, sex-, and race-adjusted prevalence rates of Given the large size of our database, we were able to control for patient age, gender, and month of testing. We had enough patient records to match patients into clinically relevant strata of 25(OH)D levels: <20 , 20-29, and 30-100 ng/ml. Therefore, we were able to achieve higher statistical power to identify clinically significant relationships, which show a step-wise association of higher 25(OH)D levels with better lipid panel results. Furthermore, compared to NHANES III, our data contained a greater proportion of patients with hypertension (32.5% vs.
28.4%) and diabetes (29.9% vs. 8.4%), which is more reflective of the patient population at increased cardiovascular risk and those seeking medical care. 17 The difference in lipid levels between the optimal and deficient vitamin D groups in our cross-sectional study suggests a possible 12% reduction in the imputed relative risk of cardiovascular disease! 22, 23 Association studies, however, do not prove cause and effect.
RCT have been published to investigate a causal relationship between vitamin D supplementation and changes in the lipid panel. [5] [6] [7] [8] [9] 11 The largest was the Women's Health Initiative (WHI). A subgroup analysis of 1,191 women found no effect of vitamin D supplementation on lipids over a 5-year period. 7 However, the WHI highlights many pitfalls common to prior studies, preventing a definitive conclusion of the effect of vitamin D repletion on lipids. 24 First, many study participants were not vitamin D deficient at baseline. Furthermore, the dose of vitamin D (400 IU per day) was likely too small to meaningfully separate treatment and placebo groups, especially when subjects in both arms were allowed to take non-study vitamin D supplements. A third limitation was the co-administration of calcium supplements, which may have confounded the effect of vitamin D. There was also relatively poor compliance:
ncreased cardiovascular risk and those seeking medical care. 17 The difference in lipid levels between the optimal and deficient vitamin D groups in our A new generation of vitamin D supplementation trials may provide more definitive evidence of vitamin D supplementation on heart disease outcomes. 21 These well-powered trials use a higher dose of vitamin D than the WHI and will test the effect of vitamin D without calcium. However, they do not specifically target vitamin D deficiency and the results will be unavailable for several years.
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Therefore, we believe our sensitivity analysis validates the use of database rules to exclude patients who are most likely impacted by large, first-order confounding effects outside the scope of the scientific inquiry being pursued.
Also, we do not know the clinical rational for why these patients underwent vitamin D and lipid testing, which may represent other confounding factors. We explored the sensitivity of our results to potential confounding, latent effects that might have been present in baseline characteristics. We developed a propensity score model to define repletion and control groups.
We built a logistic regression model that tries to explain membership in the repletion group using available baseline characteristics. Statistically significant predictors included age, initial 
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